Join Growin Stock Community!

全福生技6885.TW Overview

TW StockBiotech. & Medical
(No presentation for 6885)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

全福生技（6885）Overall Performance

全福生技（6885）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

全福生技（6885） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

全福生技（6885）Key Information

全福生技（6885）Profile

BRIM Biotechnology, Inc., a clinical-stage company, engages in the development of novel regenerative therapies to combat and cure ophthalmology and degenerative joint diseases. The company's lead product candidate is BRM 421, a topical ophthalmic solution for patients with moderate-to-severe dry eye syndrome that has completed a phase 2 clinical trial in the United States. It is also developing BRM 423 to treat severe corneal damage, which is in phase 1 clinical trial; BRM 424 for the treatment of neurotrophic keratitis, which is in phase 1 clinical trial; and BRM 521 to relieve and repair tissue damage caused by osteoarthritis. The company was founded in 2013 and is based in Taipei, Taiwan.

全福生技（6885）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.91
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1127.62
PB Ratio
1.91
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
42.59%
Net Margin
-12222.57%
Revenue Growth (YoY)
1933.33%
Profit Growth (YoY)
1307.29%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.91
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1127.62
PB Ratio
1.91
Price-to-FCF
-
Gross Margin
42.59%
Net Margin
-12222.57%
Revenue Growth (YoY)
1933.33%
Profit Growth (YoY)
1307.29%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
default symbol

6885

全福生技

26.85D

-1.30%

(-0.01)

  • When is 6885's latest earnings report released?

    The most recent financial report for 全福生技 (6885) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6885's short-term business performance and financial health. For the latest updates on 6885's earnings releases, visit this page regularly.

  • What is the operating profit of 6885?

    According to the latest financial report, 全福生技 (6885) reported an Operating Profit of -104.45M with an Operating Margin of -8,498.54% this period, representing a decline of 60.31% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 6885's revenue growth?

    In the latest financial report, 全福生技 (6885) announced revenue of 1.23M, with a Year-Over-Year growth rate of 1,762.12%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 6885 have?

    At the end of the period, 全福生技 (6885) held Total Cash and Cash Equivalents of 721.9M, accounting for 0.37 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6885 go with three margins increasing?

    In the latest report, 全福生技 (6885) did not achieve the “three margins increasing” benchmark, with a gross margin of -13.1%%, operating margin of -8,498.54%%, and net margin of -7,135.64%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6885's profit trajectory and future growth potential.

  • Is 6885's EPS continuing to grow?

    According to the past four quarterly reports, 全福生技 (6885)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.63. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 6885?

    全福生技 (6885)'s Free Cash Flow (FCF) for the period is 6.99M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 70.89% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.